Current Landscape of Bispecific Therapies for RRMM

Key Takeaways

• Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
• Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
• Ongoing research focuses on optimizing safety profiles and expanding the applicability of bispecific therapies in RRMM management.